IN2014DN05665A - - Google Patents

Download PDF

Info

Publication number
IN2014DN05665A
IN2014DN05665A IN5665DEN2014A IN2014DN05665A IN 2014DN05665 A IN2014DN05665 A IN 2014DN05665A IN 5665DEN2014 A IN5665DEN2014 A IN 5665DEN2014A IN 2014DN05665 A IN2014DN05665 A IN 2014DN05665A
Authority
IN
India
Prior art keywords
nucleic acid
acid molecule
nucleotides
central stretch
deoxyribonucleotides
Prior art date
Application number
Other languages
English (en)
Inventor
Kai Höhlig
Axel Vater
Klaus Buchner
Christian Maasch
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of IN2014DN05665A publication Critical patent/IN2014DN05665A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
IN5665DEN2014 2012-01-10 2013-01-10 IN2014DN05665A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (1)

Publication Number Publication Date
IN2014DN05665A true IN2014DN05665A (cg-RX-API-DMAC7.html) 2015-05-15

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5665DEN2014 IN2014DN05665A (cg-RX-API-DMAC7.html) 2012-01-10 2013-01-10

Country Status (18)

Country Link
US (5) US9518265B2 (cg-RX-API-DMAC7.html)
EP (1) EP2802660B1 (cg-RX-API-DMAC7.html)
JP (1) JP6415327B2 (cg-RX-API-DMAC7.html)
KR (1) KR102034203B1 (cg-RX-API-DMAC7.html)
CN (1) CN104145018B (cg-RX-API-DMAC7.html)
AU (2) AU2013209131A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014016877B1 (cg-RX-API-DMAC7.html)
CA (1) CA2860806C (cg-RX-API-DMAC7.html)
DK (1) DK2802660T3 (cg-RX-API-DMAC7.html)
ES (1) ES2786007T3 (cg-RX-API-DMAC7.html)
IL (1) IL233516B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN05665A (cg-RX-API-DMAC7.html)
MX (1) MX362061B (cg-RX-API-DMAC7.html)
PL (1) PL2802660T3 (cg-RX-API-DMAC7.html)
PT (1) PT2802660T (cg-RX-API-DMAC7.html)
RU (1) RU2645261C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201605594UA (cg-RX-API-DMAC7.html)
WO (1) WO2013104540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
WO2019222340A1 (en) 2018-05-17 2019-11-21 The Procter & Gamble Company Systems and methods for hair coverage analysis
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
EP3814504A1 (en) 2018-06-29 2021-05-05 The Procter & Gamble Company Aptamers for personal care applications
JP2022512969A (ja) * 2018-11-12 2022-02-07 アプタリオン バイオテック エージー Cxcl8結合核酸
MX2021012433A (es) 2019-04-16 2021-11-17 Procter & Gamble Aptameros para aplicaciones para el control de olor.
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor
WO2025196240A1 (en) 2024-03-20 2025-09-25 Aptarion Biotech Ag Method of treating a disorder with a c5a inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
DK1438321T5 (da) 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
FI20051017A7 (fi) 2003-04-13 2005-11-28 Enzon Pharmaceutivals Inc Polymeeriset oligonukleotidiaihiolääkkeet
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP1713509A2 (de) 2004-02-09 2006-10-25 Noxxon Pharma AG Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
EP2578683B9 (en) * 2004-02-12 2015-04-15 Archemix LLC Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1807092B1 (en) 2004-11-05 2016-09-07 The Children's Hospital of Philadelphia Biodegradable linkers for molecular therapies
JP2008526915A (ja) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト C5a受容体アンタゴニスト
CN104623692A (zh) 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
EP2063709A2 (en) 2006-09-15 2009-06-03 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
AU2008303775A1 (en) 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a binding nucleic acids
JP4642940B2 (ja) 2009-03-11 2011-03-02 オリンパスメディカルシステムズ株式会社 画像処理システム、その外部装置およびその画像処理方法
US20120065254A1 (en) 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
EP2663640B1 (en) * 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
SG11201401362TA (en) 2011-10-21 2014-05-29 Noxxon Pharma Ag Glucagon binding nucleic acids
KR20140111704A (ko) 2012-01-10 2014-09-19 녹손 파르마 아게 Cgrp에 특이적으로 결합하는 핵산

Also Published As

Publication number Publication date
PL2802660T3 (pl) 2020-07-27
SG10201605594UA (en) 2016-09-29
CN104145018A (zh) 2014-11-12
DK2802660T3 (da) 2020-05-18
JP6415327B2 (ja) 2018-10-31
US20180223285A1 (en) 2018-08-09
US20210163946A1 (en) 2021-06-03
JP2015509705A (ja) 2015-04-02
US20240384275A1 (en) 2024-11-21
KR20140111703A (ko) 2014-09-19
EP2802660B1 (en) 2020-02-19
WO2013104540A1 (en) 2013-07-18
EP2802660A1 (en) 2014-11-19
BR112014016877A2 (pt) 2019-10-29
US20140364487A1 (en) 2014-12-11
SG11201403771SA (en) 2014-07-30
CA2860806C (en) 2020-10-20
CN104145018B (zh) 2019-05-10
PT2802660T (pt) 2020-04-21
ES2786007T3 (es) 2020-10-08
US10590424B2 (en) 2020-03-17
US20250327082A1 (en) 2025-10-23
RU2014132708A (ru) 2016-02-27
MX362061B (es) 2019-01-07
AU2018271388A1 (en) 2018-12-20
US11492625B2 (en) 2022-11-08
US12188021B2 (en) 2025-01-07
AU2018271388B2 (en) 2021-03-11
KR102034203B1 (ko) 2019-10-18
IL233516B (en) 2018-07-31
AU2013209131A1 (en) 2014-07-10
US9518265B2 (en) 2016-12-13
BR112014016877B1 (pt) 2022-03-15
RU2645261C2 (ru) 2018-02-19
IL233516A0 (en) 2014-08-31
HK1198371A1 (en) 2015-04-10
MX2014008454A (es) 2015-02-05
CA2860806A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
IN2014DN05665A (cg-RX-API-DMAC7.html)
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
UA118014C2 (uk) Спосіб модифікації днк-мішені
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
IN2012DN00403A (cg-RX-API-DMAC7.html)
IL250539B (en) Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
PH12015501953A1 (en) Substituted nucleotide analogs
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
MX2010003109A (es) Acidos nucleicos de enlace c5a.
IN2014CN02574A (cg-RX-API-DMAC7.html)
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2011106766A3 (en) Modified proteins and methods of making and using same
UA101806C2 (ru) Одноцепочечная кольцевая рнк и способ ее получения
MX2011003229A (es) Terapia genica con porfobilinogeno desaminasa.
MX343918B (es) Construccion de adn inmunomodulador no codificante.
EP2488641A4 (en) SUPERGESPULED MINICIRCLE DNA FOR GENE THERAPY APPLICATIONS
WO2010107955A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
UY33668A (es) ?composiciones de las paredes celulares de ácido ribonucleico bacteriano, y métodos para elaborarlas y usarlas?.
WO2012011114A3 (en) Sequence specific double-stranded dna/rna binding compounds and uses thereof
ATE536360T1 (de) Neues nukleinsäuretransfersystem
MX377713B (es) Moleculas de ácido ribonucleico pequeño de interferencia especifico de notch 1.
WO2009143277A3 (en) Compositions comprising hscn9a sirna and methods of use thereof